Significant improvements were observed in multiple renal parameters, indicating effective treatment.
A notable reduction in adverse events was recorded, highlighting treatment safety for patients.
Analyses compare the combined effects of both semaglutide and canagliflozin to canagliflozin alone, emphasizing synergy.
Benefits observed imply potential advantages of combined therapies for diabetic nephropathy management.
Abstract
CSCT provided significant improvements in multiple metabolic and renal parameters without increasing adverse events, thus highlighting its potential benefits for patients with DN.